HU9602122D0 - Camptothecin derivatives - Google Patents

Camptothecin derivatives

Info

Publication number
HU9602122D0
HU9602122D0 HU9602122A HUP9602122A HU9602122D0 HU 9602122 D0 HU9602122 D0 HU 9602122D0 HU 9602122 A HU9602122 A HU 9602122A HU P9602122 A HUP9602122 A HU P9602122A HU 9602122 D0 HU9602122 D0 HU 9602122D0
Authority
HU
Hungary
Prior art keywords
group
lower alkyl
formula
alkyl group
camptothecin derivatives
Prior art date
Application number
HU9602122A
Other languages
English (en)
Inventor
Takayuki Kawaguchi
Satoshi Okuno
Kenji Tsujihara
Toshiro Yano
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of HU9602122D0 publication Critical patent/HU9602122D0/hu
Publication of HUP9602122A2 publication Critical patent/HUP9602122A2/hu
Publication of HUP9602122A3 publication Critical patent/HUP9602122A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9602122A 1995-08-02 1996-08-01 Camptothecin derivatives, process for the preparation thereof and pharmaceutical compositions containing them HUP9602122A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP19739195 1995-08-02
JP34061995 1995-12-27
JP17337296 1996-07-03

Publications (3)

Publication Number Publication Date
HU9602122D0 true HU9602122D0 (en) 1996-09-30
HUP9602122A2 HUP9602122A2 (en) 1997-11-28
HUP9602122A3 HUP9602122A3 (en) 1998-07-28

Family

ID=27323772

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9602122A HUP9602122A3 (en) 1995-08-02 1996-08-01 Camptothecin derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Country Status (20)

Country Link
US (1) US5837673A (hu)
EP (1) EP0757049B1 (hu)
KR (1) KR100387191B1 (hu)
CN (2) CN1143859C (hu)
AT (1) ATE178067T1 (hu)
AU (1) AU717653B2 (hu)
BG (1) BG63342B1 (hu)
CA (1) CA2182244C (hu)
DE (1) DE69601841T2 (hu)
DK (1) DK0757049T3 (hu)
ES (1) ES2131913T3 (hu)
GR (1) GR3029796T3 (hu)
HK (1) HK1005545A1 (hu)
HU (1) HUP9602122A3 (hu)
IL (1) IL118957A (hu)
MY (1) MY116665A (hu)
NO (1) NO315469B1 (hu)
RU (1) RU2138503C1 (hu)
SG (1) SG50747A1 (hu)
TW (1) TW466242B (hu)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
DE19640207A1 (de) * 1996-09-30 1998-04-02 Bayer Ag Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung)
ATE210673T1 (de) * 1996-09-30 2001-12-15 Bayer Ag Glycokonjugate von modifizierten camptothecin- derivaten (20-o-verknüpfung)
TW464652B (en) * 1996-10-30 2001-11-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US20030166513A1 (en) * 2000-06-29 2003-09-04 Akihiro Imura Dds compound and process for the preparation thereof
BR0115260A (pt) 2000-11-09 2005-08-16 Neopharm Inc Complexos de sn-38 com lipìdeos e seus usos no tratamento de doenças
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
PT1580216E (pt) * 2002-10-31 2014-07-31 Nippon Kayaku Kk Derivados de elevado peso molecular de camptotecinas
WO2004092205A1 (en) * 2003-04-16 2004-10-28 Debio Recherche Pharmacuetique S.A. Hydroxy-substituted-20-acyloxy-camptothecin polymer derivatives and use of the same for the manufacture of a medicament
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
KR20120073370A (ko) * 2003-09-17 2012-07-04 넥타르 테라퓨틱스 다분지형 고분자 전구약물
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
CA2581125C (en) 2004-09-22 2013-04-23 Nippon Kayaku Kabushiki Kaisha Modified poly(ethylene oxide-amino acid) copolymer, micelle preparation, and anticancer agent containing the same
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
TWI375678B (en) 2005-06-09 2012-11-01 Yakult Honsha Kk A method of preparation of a tricyclic ketone
ITFI20050246A1 (it) * 2005-12-02 2007-06-03 Menarini Internat Operations Luxembourg Sa Uso di un composto comprendente un derivato della camptotecina per la preparazione di formulazioni farmaceutiche utili nel trattamento del melanoma
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
CN101448875A (zh) 2006-05-18 2009-06-03 日本化药株式会社 鬼臼毒素类的高分子量结合体
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
EP2090607B1 (en) 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
EP2104515B1 (en) 2006-11-30 2018-11-14 Nektar Therapeutics Method for preparing a polymer conjugate
CA2677798A1 (en) 2007-02-09 2008-08-14 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CN101808651B (zh) 2007-09-28 2013-03-27 日本化药株式会社 类固醇类的高分子结合物
US8920788B2 (en) 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
KR20230133952A (ko) 2008-04-30 2023-09-19 이뮤노젠 아이엔씨 가교제 및 그 용도
EP2284209B1 (en) 2008-05-08 2016-08-31 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
WO2010019233A1 (en) 2008-08-11 2010-02-18 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
MX2011003063A (es) 2008-09-23 2011-04-21 Nektar Therapeutics Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo.
WO2010131675A1 (ja) 2009-05-15 2010-11-18 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
EP2641605B1 (en) 2010-11-17 2018-03-07 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolism antagonist
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
ES2556985T3 (es) 2011-01-11 2016-01-21 Capsugel Belgium Nv Nuevas cápsulas duras que comprenden pululano
CN103874722B (zh) 2011-09-11 2016-06-29 日本化药株式会社 嵌段共聚物的制造方法
AU2013328111B2 (en) 2012-10-11 2017-11-02 Daiichi Sankyo Company, Limited Antibody-drug conjugate
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
MY195162A (en) 2013-12-25 2023-01-11 Daiichi Sankyo Co Ltd Anti-Trop2 Antibody-Drug Conjugate
LT3466976T (lt) 2014-01-31 2021-11-10 Daiichi Sankyo Company, Limited Anti-her2 antikūno-vaisto konjugatas
AU2015245122B2 (en) 2014-04-10 2019-10-24 Daiichi Sankyo Company, Limited Anti-HER3 antibody-drug conjugate
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
WO2017002776A1 (ja) 2015-06-29 2017-01-05 第一三共株式会社 抗体-薬物コンジュゲートの選択的製造方法
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
WO2018135501A1 (ja) 2017-01-17 2018-07-26 第一三共株式会社 抗gpr20抗体及び抗gpr20抗体-薬物コンジュゲート
AU2018253392B2 (en) 2017-04-14 2023-11-02 Capsugel Belgium Nv Process for making pullulan
CN110678170A (zh) 2017-04-14 2020-01-10 比利时胶囊公司 普鲁兰多糖胶囊
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
CA3073924C (en) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
IL272964B2 (en) 2017-08-31 2024-02-01 Daiichi Sankyo Co Ltd Production method for antibody-drug conjugates
TW202402806A (zh) 2018-05-18 2024-01-16 日商第一三共股份有限公司 抗muc1抗體藥物複合體
WO2024020734A1 (en) * 2022-07-25 2024-02-01 Immunogen, Inc. Novel processes for preparing camptothecin derivatives

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0220601B1 (en) * 1985-10-21 1991-12-11 Daiichi Seiyaku Co., Ltd. Pyranoindolizine derivatives and preparation process thereof
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5049668A (en) * 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
JP2540357B2 (ja) * 1987-06-24 1996-10-02 第一製薬株式会社 六環性化合物
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
DE69033880T2 (de) * 1989-09-15 2002-06-06 Research Triangle Institute, Research Triangle Park Verfahren zur herstellung von 10,11-Methylendioxy-20(RS)-Camptothecin und 10,11-Methylendioxy-20(S)-Camptothecin-Analog
WO1991004260A2 (en) * 1989-09-15 1991-04-04 Research Triangle Institute 10,11-methylenedioxy-20(rs)-camptothecin and 10,11-methylenedioxy-20(s)-camptothecin analogs
US5140010A (en) * 1989-09-28 1992-08-18 Immunobiology Research Institute Stabilized aqueous formulations of thymopentin
EP0544000B1 (en) * 1990-08-17 1997-05-02 Drug Delivery System Institute, Ltd. N-acetylcarboxymethylchitosan derivative and production thereof
EP0540099B1 (en) * 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
JPH06228141A (ja) * 1992-01-24 1994-08-16 Takeda Chem Ind Ltd 縮合複素環誘導体、その塩、その製造法および用途
CA2087898A1 (en) * 1992-01-24 1993-07-25 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
AU3611093A (en) * 1992-02-21 1993-09-13 Smithkline Beecham Corporation Substituted furo(3',4':6,7)indolizino(1,2-b)quinolinones
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
ATE195324T1 (de) 1993-02-26 2000-08-15 Drug Delivery System Inst Ltd Polysaccharidderivat und wirkstoffträger
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives

Also Published As

Publication number Publication date
HUP9602122A3 (en) 1998-07-28
DE69601841D1 (de) 1999-04-29
CA2182244C (en) 2004-02-03
DE69601841T2 (de) 1999-08-05
NO315469B1 (no) 2003-09-08
AU717653B2 (en) 2000-03-30
BG100758A (bg) 1997-02-28
HUP9602122A2 (en) 1997-11-28
CN1145365A (zh) 1997-03-19
EP0757049B1 (en) 1999-03-24
IL118957A0 (en) 1996-10-31
US5837673A (en) 1998-11-17
CA2182244A1 (en) 1997-02-03
GR3029796T3 (en) 1999-06-30
CN1075501C (zh) 2001-11-28
CN1308078A (zh) 2001-08-15
BG63342B1 (bg) 2001-10-31
KR100387191B1 (ko) 2003-10-04
ATE178067T1 (de) 1999-04-15
ES2131913T3 (es) 1999-08-01
NO963214D0 (no) 1996-08-01
KR19980013708A (ko) 1998-05-15
IL118957A (en) 2000-11-21
RU2138503C1 (ru) 1999-09-27
CN1143859C (zh) 2004-03-31
DK0757049T3 (da) 1999-06-23
MY116665A (en) 2004-03-31
AU6069896A (en) 1997-02-06
HK1005545A1 (en) 1999-01-15
EP0757049A1 (en) 1997-02-05
SG50747A1 (en) 1998-07-20
NO963214L (no) 1997-02-03
TW466242B (en) 2001-12-01

Similar Documents

Publication Publication Date Title
SG50747A1 (en) Comptothecin derivatives
SG76585A1 (en) Camptothecin derivatives
HUT59163A (en) Process for producing peptide derivatives and pharmaceutical compositions containing them
TW357146B (en) Tetrahydrofuran antifungals
FI891176A0 (fi) Peptidfoereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
TW222584B (hu)
EP0870765A4 (hu)
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
IL90424A0 (en) Cephem derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
RS91204A (en) Lyophilized and liquid preparation comprising a polysaccharide derivative of camptothecin
US5330978B1 (en) Phosphonic acid derivatives and use thereof
MX9603149A (es) Derivados de camptotecina.
EP0573659A4 (en) Pyrazolothiazolopyrimidine derivative

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

Free format text: FORMER OWNER(S): TANABE SEIYAKU CO. LTD., JP

FD9A Lapse of provisional protection due to non-payment of fees